Comparison diagnostic performance of 18F-Flurodeoxyglucose and 18F-Floroestradiol Positron Emission Tomography/Computed Tomography for Initial Staging in Estrogen Receptor Positive Breast Cancer Patients.

Head-to-Head Comparison of 18F FDG and 18F FES PET/CT for Initial Staging of ER-Positive Breast Cancer Patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20230603002

Enrollment

185

Registered

2023-06-03

Start date

2022-03-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Initial staging in ER-positive breast cancer 18F-FDG, 18F-FES, 18F-Fluorodeoxyglucose, 18F-Fluroestradiol, ER-positive breast cancer

Interventions

Patients with pathological confirmed breast cancer with ER positive who were scheduled for PET imaging for initial staging.

Diagnostic

ER-positive breast cancer patients

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (i) patients with pathologically confirmed breast cancer with estrogen receptor (ER) positive and (ii) patients who were > 18 years old

Exclusion criteria

Exclusion criteria: (i) patients with fasting blood sugar more than 200 mg/dL; (ii) patients who has history of other cancer; (iii) patients with known ER negative, (iv) patients with unknown ER status; and (iii) patients who were pregnant or during breast feed.

Design outcomes

Primary

Measure	Time frame
Diagnostic performance of FDG and FES PET/CT at the time of intervention (PET/CT interpretation) sensitivity, specificity, PPV, NPV, and accuracy	—

Secondary

Measure	Time frame
Concordant rate of FDG and FES PET-CT at the time of intervention (PET/CT interpretation) concordant rate,Factor affect degree of FDG and FES uptake at the time of intervention (PET/CT interpretation) Multi-linear regression analysis	—

Countries

Thailand

Contacts

Public ContactChanisa Chotipanich

National Cyclotron and PET Centre, Chulabhorn Hospital

ncpc.cyclo2m@gmail.com0960918369

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026